Mukotik Carbocisteine (mucodyne) 250 Mg 50 Tablets

Active ingredient

Carbocisteine ​​250 mg
Excipients

Lactose monohydrate (from bovine) 80 mg
4. CLINICAL FEATURES

    4.1. Therapeutic indications

    It is used as an adjunctive therapy in acute and chronic respiratory tract diseases characterized by excessive mucus formation and in secretory otitis media.
        4.2. Posology and method of administration

        Posology / application frequency and duration:

        In adults, including the elderly:

        Dosage is based on an initial daily dose of 2250mg Carbocysteine ​​in divided doses; When a satisfactory effect is achieved, it is reduced to 1500 mg per day in divided doses, for example from 3 tablets three times a day to 2 tablets three times a day.

        Method of Application:

        It is taken orally.

        Additional information on special populations:

        Kidney / Liver failure:

        The above mentioned doses are used.

        Pediatric population:

        In children:

        This formulation is not recommended for children. The usual daily dose is 20 mg / kg body weight in divided doses. For this, it is recommended to use Mucotic Pediatric Syrup.

        Geriatric population:

        The dosage stated above is used.
            4.3. Contraindications

            It should not be used in those who are hypersensitive to the active substance or the excipients in its composition.

            It should not be used in patients with active gastric and duodenal ulcers.
                4.4. Special use warnings and precautions

                During the use of the drug in normal doses, there may be an increase in the amount of expectorated sputum. If there is excessive obstruction in the lungs and respiratory tract, if the cough required to expel the mucus particles is not sufficient, the obstruction in the respiratory tract can be eliminated by mechanical aspiration.

                Since bronchospasm may occur during the treatment of asthmatic patients, it should be given with caution. It should not be used if symptoms are seen.

                Caution is advised in the elderly, those with a history of gastroduodenal ulcer, or those with drugs known to cause gastrointestinal bleeding. If gastrointestinal bleeding occurs, patients should discontinue the drug.

                MUCOTIC contains lactose (originating from bovine). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
                    4.5. Interaction with other medicinal products and other forms of interaction

                    It is incompatible with Folkodin. Its mixture with folcodine causes carbocysteine ​​to precipitate. It is recommended not to use the opiate derivative at the same time as these types of compounds.
                        4.6. Pregnancy and lactation

                        General advice

                        Pregnancy category: B

                        Women with childbearing potential / Contraception (Contraception)

                        The effects of carbocysteine ​​on women of childbearing potential and contraception are unknown.

                        Gestation period

                        For mucotic, no clinical data on exposure to pregnancies are available. Animal studies do not indicate harmful effects with respect to pregnancy / embryonal / fetal development / birth or postnatal development, or indirectly.

                        Caution should be exercised when administered to pregnant women.

                        Although there is no teratogenic effect in the experiments, it is recommended not to be used in the first trimester of pregnancy.

                        Lactation period

                        It is not known whether the mother's milk. Since many drugs pass into breast milk, care should be taken when administering the Mucotic tablet to a nursing mother.

                        Reproductive ability / Fertility

                        Effects on fertility and fertility are unknown.
                            4.7. Effects on ability to drive and use machines

                            There is no information on this matter.
                                4.8. Unwanted effects

                                Frequencies are defined as follows: Very common (> 1/10); common (> 1/100, <1/10); uncommon (> 1/1000, <1/100); rare (> 1 / 10,000, <1/1000); very rare (<1 / 10,000); unknown (cannot be estimated from the available data).

                                Immune system disorders

                                Not known: Anaphylactic reactions and pronounced drug eruption

                                Nervous system disorders

                                Not known: headache

                                Gastrointestinal diseases

                                Rare: Gastrointestinal bleeding.

                                Not known: Nausea, vomiting, haemoptysis, stomach discomfort, diarrhea